BioNTech SE
BNTX News Today: Stay Updated with the Latest BioNTech SE News in Real Time
Find BNTX news now at Meyka AI. Stay informed with the latest BioNTech SE stocks updates, including price news, market analysis, and expert insights.
BNTX BioNTech SE Earnings: Beat EPS, Missed Revenue
BioNTech beat EPS by 3.72% but missed revenue by 34.22%. Q1 2026 earnings show mixed results for the biotech company.
22UA.F BioNTech SE Earnings Beat EPS, Misses Revenue
BioNTech SE (22UA.F) beat EPS estimates by 11.24% but missed revenue by 34.22% in Q1 2026 earnings.
GMAB Earnings Preview: Genmab Q1 2026 on May 7
Genmab (GMAB) reports Q1 2026 earnings May 7. Analysts expect $0.15 EPS, $905.77M revenue. Stock at $27.52.
COVID-19 Vaccination: Facts on April 26 Safety & Efficacy
COVID-19 vaccination facts: Debunking false death claims with actual safety data, efficacy rates, and verified side effects from health authorities.
BNTX Analyst Rating Maintained at Overweight by Morgan Stanley
Morgan Stanley maintains BNTX analyst rating at Overweight, raises price target to $126 on April 10, 2026.
BNTX Stock Today: March 31: ELCC Cancer Data Steady Amid Biotech Rout
BioNTech stock holds near $85 as biotech volatility hits peers. ELCC cancer data on gotistobart showed 54% lower death risk in advanced lung cancer, supporting medium-term catalysts for German traders
BNTX Stock Today: March 30 — ELCC Data Show 54% Lower Death Risk
BioNTech stock: ELCC 2026 data show 54% lower death risk in advanced lung cancer. What it means for German investors, valuation, catalysts, and technicals.
Top 10 Stocks to Buy or Sell Today as Market Volatility Rises
Global stocks market are showing strong volatility in March 2026 as traders digest conflicting signals from geopolitical tensions, rising energy prices, and economic data. The CBOE Volatility Index (VIX), often called Wall Street’s fear gauge, swung sharply this week, jumping above key levels then retreating as markets tried to regain balance. This turbulence is influencing…
BNTX BioNTech SE March 11, 2026 BMO Maintains Outperform
BNTX analyst rating: BMO maintains Outperform March 11, 2026 and lowers price target to $128